Neogen (NEOG) Peer Comparison
$11.73
$0.09
(0.73%)
As on 04-Sep-2026 11:36EDT
Market cap
$2,543 Mln
Revenue (TTM)
$870 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Edit
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,543 | 655 | 372 | 33 | 32,953 |
Revenue ($ Mln) |
870 | 320 | 82 | 402 | 5,653 |
Net Profit ($ Mln) |
-7.90 | -36.74 | 8.11 | -49.19 | 1,523.29 |
Net Margin (%) |
-0.91 | -11.48 | 9.88 | -12.24 | 26.94 |
RoE (%) |
-0.38 | -20.77 | 6.09 | -80.08 | 24.27 |
Price to Earnings |
-- | -- | 45.98 | -- | 22.11 |
Price-To-Book |
1.22 | 3.82 | 2.68 | 0.75 | 5.05 |
Income Statement ($ Mln)
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
870.40 | 320.17 | -- | 401.95 | 5,653.44 |
|
Cost of Revenue
|
461.90 | 145.28 | -- | 290.49 | 2,195.77 |
|
Gross Profit
|
408.50 | 174.89 | -- | 111.45 | 3,457.68 |
|
Operating Expenses
|
430.10 | 214.82 | -- | 137.90 | 1,565.03 |
|
Operating Profit (EBIT)
|
-21.60 | -39.93 | -- | -26.44 | 1,892.65 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-9.00 | -36.30 | -- | -47.25 | 1,919.42 |
|
Provision for Tax
|
-1.10 | 0.44 | -- | 1.95 | 396.12 |
|
Profit after Tax (Net Income)
|
-7.90 | -36.74 | -- | -49.19 | 1,523.29 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,092.90 | 170.83 | -- | 41.70 | 6,585.39 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
1,094.90 | 21.62 | -- | 210.57 | 985.45 |
|
Current Liabilities
|
158.20 | 74.72 | -- | 191.41 | 1,395.11 |
|
Total Liabilities
|
3,346.00 | 267.16 | -- | 443.68 | 8,965.95 |
Assets ($ Mln)
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,741.40 | 103.77 | -- | 156.18 | 4,641.21 |
|
Current Assets
|
604.60 | 163.39 | -- | 287.50 | 4,324.74 |
|
Total Assets
|
3,346.00 | 267.16 | -- | 443.68 | 8,965.95 |
|
Total Debt*
|
793.70 | -- | -- | 183.87 | 825.92 |
|
Net Current Assets
|
446.40 | 88.68 | -- | -- | -- |
Cashflow ($ Mln)
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
83.20 | 3.09 | -- | -6.98 | 1,805.83 |
|
Cash Flow from Investing Activities
|
70.50 | -5.95 | -- | -12.28 | -545.20 |
|
Cash from Financing Activities
|
-99.40 | 0.56 | -- | 6.98 | -1,007.03 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-0.27 | -20.19 | -- | -20.37 | 21.41 |
|
ROE (%)
|
-0.38 | -20.77 | -- | -80.08 | 24.27 |
|
ROA (%)
|
-0.23 | -13.43 | -- | -10.77 | 17.77 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-0.91 | -11.48 | -- | -12.24 | 26.94 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.03 | 0.09 | -- | -0.12 | 0.10 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
99.28 | -8.09 | -- | -2,992.02 | 8.75 |
|
EPS Growth (%)
|
-- | -- | -- | -26.45 | 0.10 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -- | -- | -0.64 | 18.55 |
|
Price / Book Value
|
-- | -- | -- | 0.76 | 4.29 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
3.57 | -286.51 | -- | -12.15 | 12.86 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.38 | -- | -- | 4.41 | 0.13 |
|
Short term debt to equity ratio
|
-- | -- | -- | 0.23 | 0.04 |
|
Current Ratio
|
3.82 | 2.19 | -- | 1.50 | 3.10 |
|
Quick Ratio
|
2.91 | 1.49 | -- | 0.73 | 2.42 |
|
Interest Coverage
|
0.84 | -75.14 | -- | -- | 67.12 |
Operating Efficiency Ratios
| Neogen (NEOG) | AngioDynamics (ANGO) | Simulations Plus (SLP) | Accuray (ARAY) | ResMed (RMD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.87 | 15.09 | -- | 16.77 | 18.33 |
|
Asset Turnover
|
0.26 | 1.17 | -- | 0.88 | 0.66 |
|
Receivable days
|
62.98 | 52.17 | -- | 75.09 | 65.48 |
|
Inventory Days
|
132.51 | 143.86 | -- | 181.12 | 155.82 |
|
Payable days
|
62.75 | 81.46 | -- | 46.89 | 48.83 |
|
Cash Conversion Cycle
|
132.75 | 114.57 | -- | 209.32 | 172.47 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
